About EP Vantage

Written by a team of experienced journalists, EP Vantage provides timely financial analysis of regulatory and patent decisions, marketing approvals, licensing deals, and M&A, giving fresh angles and insight to both current and future industry triggers.

EP Vantage was launched in 2007 by EvaluatePharma, the premier source for pharma and biotech analysis. Our unique access to EvaluatePharma Alpha’s Calendar of Events allows coverage of potential market catalysts weeks and even months ahead of other industry sources while Alpha’s NPV (Net Present Value) Analyzer puts events into context, quantifying the impact on product and company valuation.

After just two years of publishing, EP Vantage is already being recognised by the industry for perceptive and penetrating coverage of the sector with our recent nomination for Commentator of the Year at the European Mediscience Awards in London.

What our readers are saying about EP Vantage:

“Someone’s actually thought about what’s happened, as opposed to just writing about it....”
Strategy Director, European based global pharmaceutical company

“Terrific info”
Senior Healthcare banker, European investment bank

“I make a point to read every EP Vantage article that gets posted. I gain a deeper understanding of the complex mesh of issues we in the pharma industry are facing as we progress through this time of business model review.”
Manager, Competitor & Scientific Intelligence, European based global pharmaceutical company